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Chapter 9
Heavy menstrual bleeding (HMB) affects around 30% of women at some time 
during their reproductive years making it a common reason for gynaecological 
consultations in both primary and secondary care. It has a negative impact on 
a woman’s quality of life, influencing physical, emotional, sexual and social well-
being. In view of its high prevalence and major impact on quality of life, effective 
treatment is important.
In most women with HMB no underlying pathology is found and various treatment 
options can be considered to reduce the amount of menstrual bleeding, including 
pharmacological and surgical treatments. Pharmacological treatments include 
non-hormonal therapies: tranexamic acid or non-steroidal anti-inflammatory 
drugs (NSAIDs), and hormonal therapies: progestogens, combined hormonal 
contraception and the levonorgestrel-releasing intrauterine system (LNG-IUS). 
The LNG-IUS has been shown to be more effective in the treatment of HMB 
compared to oral medication. Nevertheless, around 40% of women discontinue 
the LNG-IUS within two years, because of a lack of effectiveness or side effects. 
Alternative surgical treatments include endometrial ablation and hysterectomy. 
While hysterectomy is a definitive solution, it is also an invasive option, with a risk 
of serious complications. Endometrial ablation is a minimally invasive alternative 
that aims to destroy or remove the endometrial tissue with high satisfaction rates 
and reported reintervention rates around 10-20%.
In daily practice both endometrial ablation and LNG-IUS are frequently used 
treatments in women with HMB. Because of limited evidence, these is no evidence-
based advice regarding the preference for either LNG-IUS or endometrial ablation.
This thesis focuses on the effectiveness of the LNG-IUS compared to endometrial 
ablation, including the cost-effectiveness. Furthermore, it provides insight in 
patient preference and investigates prognostic factors for failure of both LNG-IUS 
and endometrial ablation. 
Chapter 1 outlines the aim of this thesis, and is formulated in four questions:
1. Do women with heavy menstrual bleeding prefer a treatment with LNG-IUS 
or endometrial ablation?
2. What is the effectiveness of LNG-IUS compared to endometrial ablation in 
women with heavy menstrual bleeding?
3. Which treatment strategy is cost-effective, LNG-IUS or endometrial ablation?
4. Is it possible to predict failure of both LNG-IUS and endometrial ablation 




Do women with heavy menstrual bleeding prefer a treatment with 
LNG-IUS or endometrial ablation?
To answer this question, we conducted a discrete choice experiment which is 
described in chapter 2. In this study we investigated whether women with HMB 
have a preference for treatment characteristics of the LNG-IUS or endometrial 
ablation. The study was performed in general practices and at the outpatient 
gynaecology departments of two hospitals in the Netherlands. Women with HMB 
were asked to choose between hypothetical profiles containing characteristics 
of LNG-IUS or endometrial ablation. Characteristics included: (1) procedure 
performed by gynaecologist or general practitioner; (2) reversibility of the 
procedure; (3) probability of dysmenorrhea; (4) probability of irregular bleeding; 
(5) use of additional contraception; (6) need to repeat the procedure after five 
years; (7) treatment containing hormones. The main outcome measures were 
the relative importance of the characteristics and willingness to make trade-offs 
between the characteristics. In total 165 women completed the questionnaire 
and the characteristic which was found the most important was whether a 
treatment contains hormones. Women preferred a treatment without hormones, 
a treatment with the least side effects, and no need for a repeat procedure or 
additional contraception. Women completing the questionnaire at the gynaecology 
outpatient clinic differed from women in general practice in their preference 
for a definitive treatment which is performed by a gynaecologist. In conclusion 
participants preferred characteristics that were mostly related to endometrial 
ablation, but were willing to trade-off between the different characteristics.
What is the effectiveness of the LNG-IUS compared to endometrial 
ablation
Chapter 3 and 4 focuses on this question. 
Chapter 3 presents the results of a multicentre randomised controlled non-
inferiority trial comparing the effectiveness of the LNG-IUS (Mirena®) to bipolar 
radiofrequency endometrial ablation (NovaSure®) in women with HMB. The 
trial was performed in 26 hospitals and in a network of general practices in the 
Netherlands. Women aged 34 years and older, with HMB and no future pregnancy 
wish or intracavitary pathology were randomised to a treatment strategy starting 
with either the LNG-IUS or endometrial ablation. The primary outcome was blood 
loss at 24 months, measured with a Pictorial Blood Assessment Chart (PBAC)-score, 
with a non-inferiority margin of 25 PBAC points. Secondary outcomes included 
reintervention rates, patient satisfaction, quality of life, and sexual function. A 
total of 270 women were included in the trial, of which 132 women were allocated 
to the LNG-IUS (baseline PBAC-score 616 points) and 138 women to endometrial 
ablation (baseline PBAC-score 630 points). At 24 months a large decrease in 
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menstrual bleeding was seen in both groups with mean PBAC-scores of 64.8 in the 
LNG-IUS group and 14.2 in the endometrial ablation group (difference 50.5 points, 
95% confidence interval [CI] 4.3 to 96.7, non-inferiority p-value = 0.87). In the LNG-
IUS group 49 women (39%) removed the intrauterine system before the end of 
the study. 44 women (35%) in the LNG-IUS group underwent a reintervention (oral 
medication, endometrial ablation and/ or hysterectomy), compared to 27 women 
(20%) in the endometrial ablation group (relative risk [RR] 1.77; 95% CI 1.17 to 2.68). 
The most important reason for receiving a reintervention was persistence of HMB. 
No significant differences were found in hysterectomy rate, patient satisfaction, 
quality of life and sexual functioning between the groups. 
This study concludes both the LNG-IUS and endometrial ablation strategy lead to a 
large decrease in menstrual bleeding, with comparable satisfaction and quality of 
life scores after 24 months. Nevertheless, endometrial ablation results in the least 
amount of menstrual blood loss and non-inferiority of a strategy starting with the 
LNG-IUS could not be demonstrated. Women who start with the LNG-IUS were 
shown to more frequently need further treatment to achieve the desired effect, 
with a quarter of women undergoing endometrial ablation. The results of this study 
will enable physicians to provide women with HMB with clear information about 
the effectiveness of two frequently applied HMB treatments. Women should weigh 
the benefits in effectiveness of endometrial ablation, against the less-invasive and 
reversible character of the LNG-IUS, after which a well-informed decision can be made.
An important difference we found in the RCT was the number of reinterventions 
(35% of women in the LNG-IUS group versus 20% in the endometrial ablation 
group). A substantial part of women declined to participate in the RCT because of 
a preference for one of both treatments. These women were asked to participate 
in an observational cohort. As previous research showed increased satisfaction 
rates with better clinical outcomes if a patient is more involved in the choice of 
treatment and receives the treatment he or she prefers, we hypothesised that 
women in the observational cohort have lower reintervention rates compared to 
women in the RCT. In chapter 4 we report the reintervention rates of the women 
who were followed in the observational cohort and we compare the difference 
in reintervention rate between women in the cohort and women in the RCT. 
Women in the observational cohort followed the same protocol as women in 
the RCT. The primary outcome measure of this study was reintervention rate at 
24 months of follow-up.  Two hundred and seventy-six women were followed in 
the observational cohort of which 87 women preferred an initial treatment with 
LNG-IUS and 189 women preferred a treatment with endometrial ablation. At 24 
months of follow-up women in the LNG-IUS-group were more likely to receive 
a reintervention compared to women in the ablation group, 28/81 (35%) versus 




found between women in the observational cohort and women in the RCT. These 
findings endorse the findings of the RCT and show women who receive an LNG-
IUS are more likely to undergo an additional intervention compared to women 
who receive endometrial ablation, with comparable reintervention rates between 
women in the cohort and in the RCT. 
Which treatment strategy is cost-effective, LNG-IUS or endometrial 
ablation?
The direct medical costs for the LNG-IUS are lower compared to endometrial 
ablation, though a considerable part of women who receive the LNG-IUS undergo 
a reintervention. To determine the total costs of the LNG-IUS strategy and compare 
this to the endometrial ablation strategy we performed a cost-effectiveness analysis 
which is presented in chapter 5. For this analysis we used the effectiveness results 
of the RCT described in chapter 3. The PBAC was used for the assessment of effect, 
with the primary outcome for effectiveness being menstrual blood loss after 24 
months measured with the PBAC-score. For the assessment of costs both direct 
medical and direct- and indirect non-medical costs were included in the analysis. 
The incremental cost-effectiveness ratio (ICER) for both treatment strategies was 
calculated based upon menstrual blood loss and the average costs per patient 
over a 24 months’ time horizon. Total costs were €2,285 in the LNG-IUS strategy 
and €3,465 in the endometrial ablation strategy (difference: €1,180). At 24 months 
the strategy starting with the LNG-IUS was less effective (mean difference: 50.5 
PBAC points) and less costly (-€1,180; 95% CI -€2,097 to -€1,111) compared to the 
strategy starting with endometrial ablation. Endometrial ablation costed €23 per 
additional PBAC-point reduction of menstrual blood loss (ICER: €23; 95% CI €5 to 
€111). The ICER increased to €28 under the assumption that all LNG-IUS insertions 
were performed in primary care and decreased to €22 under the assumption that 
all endometrial ablations were performed at the outpatient department with 
local anaesthesia. The results indicate that a strategy starting with the LNG-IUS is 
cheaper, but slightly less effective in menstrual blood loss reduction compared to 
endometrial ablation. Depending on the success rate women are willing to accept, 
the LNG-IUS could be a cost-effective treatment option.
Is it possible to predict failure of LNG-IUS and endometrial ablation 
based upon prognostic factors?
The RCT in chapter 3 showed both the LNG-IUS and endometrial ablation are not a 
100% successful in treating HMB. To predict which women are at risk of treatment 




Chapter 6 reports a systematic review and meta-analysis on prognostic factors 
predicting failure of endometrial ablation in women with HMB. All types of studies 
reporting about prognostic factors of non-hysteroscopic endometrial ablation 
failure were included. The primary outcome was surgical reintervention rate (re-
ablation and/ or hysterectomy). Fifty-six studies with a total of 157,830 women 
(study sizes ranging from 40 to 114,910 women) and a follow-up ranging from 12 
to 120 months were included. We evaluated 10 prognostic factors: age, myomas, 
history of tubal ligation, body mass index, parity, pre-existing dysmenorrhea, 
caesarean delivery, bleeding pattern, uterus position, and uterus length. Younger 
age (aged 35 years or younger, odds ratio [OR] 1.68, 95% CI 1.19 to 2.36; aged 
40 years or younger, OR 1.58, 95% CI 1.30 to 1.93; aged 45 years or younger OR 
1.63, 95% CI 1.28 to 2.07), prior tubal ligation (OR 1.46, 95% CI 1.23 to 1.73), and 
pre-existing dysmenorrhea (OR 2.12, 95% CI 1.41 to 3.19) were associated with 
an increased risk of receiving a surgical reintervention. It is important to take the 
results of this review into account when counselling women with HMB. Women 
with one or more of these prognostic factors should be informed about the higher 
risk of failure, and alternative treatment might be considered.
Chapter 7 studies factors potentially associated with failure of LNG-IUS treatment 
in women with HMB. For this study data of the LNG-IUS arm of both the RCT and the 
observational cohort were used, described in respectively chapter 3 and 4. Eight 
potential prognostic variables (age, body mass index, caesarean section, vaginal 
delivery, previous treatment, anticoagulant use, dysmenorrhea, and pictorial 
blood assessment score) were analysed using univariable and multivariable 
regression models to estimate the risk of failure. The main outcome measure was 
discontinuation of the LNG-IUS within 24 months of follow-up, defined as removal 
of the LNG-IUS or receiving an additional intervention. A total of 201 women were 
included in the analyses. 93 women (46%) discontinued LNG-IUS treatment within 
24 months. Multivariable analysis showed younger age (aged 45 years or younger, 
RR 1.51, 95% CI 1.10 to 2.09) and severe dysmenorrhea (RR 1.36, 95% CI 1.01 to 
1.82) to be associated with a higher risk of discontinuation. The results can be 
used in the counselling of women with HMB. For future research, an analysis in 
a larger study population might be performed to identify additional prognostic 
factors for LNG-IUS failure. Furthermore, future research comparing differences 
between prognostic factors for the different treatment options for HMB might be 
helpful to further personalize counselling.
Chapter 8 provides a general discussion, clinical implications and suggestions for 
future research. 
The studies in this thesis report on multiple important outcomes for HMB treatment, 




LNG-IUS treatment and endometrial ablation lead to a large decrease in menstrual 
bleeding, with comparable satisfaction and quality of life scores. Endometrial 
ablation has some benefits in effectiveness over LNG-IUS as it has a greater 
reduction in menstrual blood loss and the risk of receiving a reintervention is lower. 
Furthermore, it was shown that women generally preferred characteristics that were 
related to endometrial ablation, with a treatment without hormones being the most 
important characteristic. However, women were willing to make trade-offs and the 
LNG-IUS has some benefits over endometrial ablation as it is less invasive, it can 
be performed by the general practitioner and has a contraceptive effect. Besides 
paying attention to women’s personal preferences, it is also important to take into 
account the presence of prognostic factors. A younger age and dysmenorrhea have 
been shown to be risk factors for failure for both the LNG-IUS and endometrial 
ablation. Prior tubal ligation additionally was a risk factor for failure of endometrial 
ablation. Taking all this information into consideration will improve the shared 
decision-making process of women with HMB.

